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Abstract
Background: Over 90% of all antibiotics in Europe are prescribed in primary care. It is important that antibiotics
are prescribed that are likely to be effective; however, information about antibiotic resistance in the community is
incomplete. The aim of our study is to investigate the appropriateness of antibiotic prescribing in primary care in
Europe by collecting and combining patterns of antibiotic resistance patterns and antibiotic prescription patterns in
primary care. We will also evaluate the appropriateness of national antibiotic prescription guidelines in relation to
resistance patterns.
Methods/Design: Antibiotic resistance will be studied in an opportunistic sample from the community in nine
European countries. Resistance data will be collected by taking a nose swab of persons (N = 4,000 per country)
visiting a primary care practice for a non-infectious disease. Staphylococcus aureus and Streptococcus pneumoniae
will be isolated and tested for resistance to a range of antibiotics in one central laboratory. Data on antibiotic
prescriptions over the past 5 years will be extracted from the electronic medical records of General Practitioners
(GPs). The results of the study will include the prevalence and resistance data of the two species and 5 years of
antibiotic prescription data in nine European countries.
The odds of receiving an effective antibiotic in each country will be calculated as a measure for the
appropriateness of prescribing. Multilevel analysis will be used to assess the appropriateness of prescribing.
Relevant treatment guidelines of the nine participating countries will be evaluated using a standardized instrument
and related to the resistance patterns in that country.
Discussion: This study will provide valuable and unique data concerning resistance patterns and prescription
behaviour in primary care in nine European countries. It will provide evidence-based recommendations for
antibiotic treatment guidelines that take resistance patterns into account which will be useful for both clinicians
and policy makers. By improving antibiotic use we can move towards controlling the resistance problem globally.
Background
Resistance to antibiotics is a growing public health pro-
blem [1-3]. The prevalence of antibiotic-resistant micro-
organisms in both hospitals and the community is
increasing [4-6]. Several studies have demonstrated that
resistance frequently leads to a delay in the administra-
tion of effective therapy, which may be associated with
increased costs, morbidity or even mortality [7,8].
A number of factors can explain the increasing trend
in resistance but high exposure to antibiotics (which
leads to a high selective pressure) is considered the
most important cause [9]. Numerous individual and eco-
logical studies have established a link between increased
antibiotic consumption and the emergence of antibiotic
resistance worldwide [10-12]. In Europe the most com-
mon exposure is the intake of antibiotic drugs, over 90%
of which is prescribed in primary care. The variability of
prescription rates is high: antibiotic use is low in north-
ern, moderate in eastern and high in southern regions
of Europe [6].
While the pharmaceutical industry is running out of
options to develop new antibiotics, a way to decrease the
exerted selective pressure is to cautiously and appropri-
ately handle antibiotic prescriptions [13]. Antibacterial
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drug use has to be both necessary and appropriate to
minimize the development of antibiotic resistance. It is
unnecessary when no antibacterial drug is indicated and
inappropriate when antibacterial treatment is indicated
but an incorrect agent is selected (inactive against the
most likely causative pathogen).
To assess the appropriateness of prescribing antibio-
tics in primary care, knowledge about likely aetiological
agents and their resistance patterns is required [14].
When General Practitioners (GPs) are provided with
data about the types and prevalence of resistant patho-
gens in their own region or country, antibiotic prescrip-
tion could be optimised [15]. However, most resistance
research has been carried out in hospital settings, and
well-documented information about community resis-
tance patterns is limited [4,16-19]. To support GPs in
optimal antibiotic prescribing, it is necessary to define
and encourage appropriate antibacterial use by utilising
national data and developing evidence-based guidelines
[20]. This study aims to fill this gap in knowledge [21],
and will analyse the appropriateness of antibiotic pre-
scribing in primary care. The main research question is:
‘To what extent is the prescribing behaviour of primary
care physicians in Europe congruent with the national
or regional community antibiotic resistance patterns?’
Our analysis is twofold: Firstly, we will determine
community resistance patterns in nine European coun-
tries and link these to the prescription behaviour of GPs
to assess their congruency. We hereby hypothesize that
higher antibiotic prescription rates are associated with
higher resistance rates. Secondly, we will evaluate the
current guidelines used by GPs with regard to the extent
to which they are congruent with national resistance
patterns, in order to make or revise recommendations, if
necessary.
The resistance patterns and prescription patterns will
be linked in this study to assess the appropriateness of
prescribing antibiotics in Europe. We will specifically
look at differences between countries, and as far as pos-
sible within countries. This article describes the design
of this study and discusses the strengths and limitations
of the study protocol. The results are expected at the
end of 2013 and will be published in separate articles.
Methods/Design
Design overview
The research question will be answered using aggre-
gated data in an ecological study design. We define the
appropriateness of prescribing as the congruency
between resistance patterns and prescription patterns;
this will be operationalised as the odds that a patient
will be given an effective drug. Data collection will be
done within the APRES study (The appropriateness of
prescribing antibiotics in primary care in Europe with
respect to antibiotic resistance). The study will be con-
ducted in nine countries in Europe: Austria, Belgium,
Croatia, France, Hungary, the Netherlands, Spain, Swe-
den and the United Kingdom. We chose to include
countries with different levels of prescription behaviour,
to maximize our analysis range.
Resistance data
Study population
a) Practices GP practices (20 per country) are recruited
through an existing GP network in each country [22].
This network should be representative of the GPs in
that country or region as much as possible, and a prere-
quisite is the ability to deliver electronic prescription
data of the participating practices for the past five years.
Geographical spread will be obtained by recruiting prac-
tices in both rural as well as urban areas. Some coun-
tries (Spain, Croatia) will also include primary care
paediatricians as these are the ones that deliver primary
care to children in these countries.
b) Patients The study will be carried out in the primary
care setting and the target population is the community
based without bacterial infections as a proxy for the
general population. We use an opportunistic random
sample of visitors of general practices. In the waiting
room information leaflets and posters are used for
recruitment purposes. All countries use the same inclu-
sion criteria:
1) No antibiotic use in the past 3 months
2) No hospitalisation in the past 3 months
3) Registered patient or regular visitor of the practice
for at least 1 year
4) Age 4 years and older (UK: 18 and over)
5) No residents of nursing homes
6) No existing infectious disease at time of visit for
which antibiotics are prescribed
7) Not immunocompromised
8) No terminal illness
9) No out of hour consultations
During the period of data collection (November 2010
- May 2011) each practice recruits 200 patients to parti-
cipate in the study. A Dutch study with the same design
proved this to be feasible [23]. The data collection is
spread across several months to maximize the potential
detection of S. pneumoniae [24].
Whether a patient meets the inclusion criteria will be
assessed by the GP or qualified practice nurse. Most cri-
teria are apparent at first sight; others are asked when
the patient is invited to participate. Regarding age and
gender we strive for an equal stratification along the dif-
ferent groups; male, female and children (4-19), middle
age (20-65) and elderly (> 65 years old). Recruitment
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will be monitored with a two-weekly update about the
recruitment.
Resistance patterns
A nasal swab is taken from all participants by the GP or
qualified practice nurse. The swabs are sent to one
laboratory in each country using special envelopes. They
should arrive within 48 hours, to increase the survival
rate of S. pneumoniae. As a consequence of the ethical
approval procedure, in the UK the nasal swabs are taken
by the patients themselves, at home. All patients from
whom a nasal swab was taken fill in a short question-
naire regarding their background and confounding vari-
ables. The national laboratories will isolate the bacteria
(Staphylococcus aureus and Streptococcus pneumoniae)
from the swabs (for the isolation procedures see addi-
tional file 1: Appendix A). These bacteria were selected
because of their high impact on health care [25]. Prior
to the swabbing period, the national laboratories are
evaluated regarding the quality of their isolation
procedures.
At the end of the data collection period, the isolated
bacteria will be sent to the Department of Medical Micro-
biology of Maastricht University, the central laboratory of
the project where the resistance testing will be performed.
The antibiotic susceptibility of the isolated strains will be
determined quantitatively using a broth dilution method
in micro-titre plates according to the EUCAST standard
[26]. The compounds tested include penicillins with and
without beta-lactamase inhibitors, cephalosporines,
macrolides, tetracyclines, quinolones, trimethoprim-sulfa-
methoxazole and rifampicin. For S. aureus also aminogly-
cosides and topical agents (fusidic acid and mupirocin)
will be tested. This analysis will result in a resistance rate
for every bacterium - antibiotic combination.
Sample size calculation
In a recent study among 2,000 community-dwelling per-
sons in the Netherlands, 23% showed to be carrier of
Staphylococcus aureus, whereas 4% showed to be resis-
tant against antibiotics [23]. Power analysis showed that
using a one-sided t-test (alpha = 0.05) testing for a 50
percent difference (4% versus 6%) between countries
with a power of 0.95, 1,000 isolates are needed. For
1,000 isolates, 4,000 swabs have to be taken in each
country. Therefore, for nine countries the total data col-
lection will consist of 36,000 swabs.
Prescription data
Study population
The GPs and GP practices who are participating in
swabbing the patients also take part in the collection of
prescription data.
Measurements
We will collect data about all prescribed antibiotics from
the participating practices for the past 5 years (i.e.
calendar years 2006 to 2011). For every prescription of
antibiotics, i.e. antibacterials for systemic use according
to the Anatomical Therapeutic Chemical (ATC) classifi-
cation (ATC code J01), we will collect the following
information:
• Date of the prescription;
• Diagnosis for which the antibiotic has been pre-
scribed (if available);
• Identification of the chemical substance (7 digit
ATC code);
• Number of packages (if available);
• Number of Defined Daily Dose (DDD’s, if
available).
The diagnostic data will be converted to the Interna-
tional Classification of Diseases,10th revision (ICD-10)
[27]. No additional data collection is needed; all these
data are routinely recorded in the patients’ electronic
medical records.
Data on characteristics of the practice population (the
epidemiological denominator) including the size of the
practice population and its age (in 5-year age bands)
and sex distribution will also be collected. In countries
with a registered list system, this file can be retrieved
from the practice computer. In countries without a
registered list system, estimates of the size and composi-
tion of the population will be provided [28] either based
on characteristics of the patients visiting the practice, or
based on extrapolation of local or regional population
characteristics [29].
Finally, each practice will provide information on a few
practice characteristics in a short questionnaire (geogra-
phical area, number of listed patients, number of physi-
cians working in the practice, age of the physicians).
Guidelines
In addition to the aforementioned data collection, rele-
vant antibiotic treatment guidelines used in the nine
participating countries will be collected and evaluated in
relation to the resistance patterns in each country. In
particular, we will focus on syndromes and diseases
mainly caused by S. aureus and S. pneumoniae: skin
infections and pneumonia respectively. In cooperation
with the GP networks in the countries, we will assess
the most frequently used primary care guidelines on
both content (specific recommendations) and quality.
For the latter we will use a standardised instrument,
with a focus on the evidence base of the recommenda-
tions [30-33].
By comparing the current resistance patterns with the
primary care guidelines per country, we will be able to
make recommendations to improve these guidelines,
incorporating the evidence we will collect.
van Bijnen et al. BMC Infectious Diseases 2011, 11:293
http://www.biomedcentral.com/1471-2334/11/293
Page 3 of 5
Ethical approval
In every participating country ethical approval for this
study has been obtained. All participants sign an
informed consent form. For children a separate form is
developed, where consent from one of their parents or
their guardian is obtained. Children are not allowed to
participate in the UK due to ethical restrictions.
Data analysis
Descriptive analyses will be carried out to calculate the
resistance patterns and patterns of prescribed antibiotics
in each country. For countries where diagnostic data are
available, more in-depth analyses will be carried out to
calculate the appropriateness of antibiotics prescribed
for specific diseases. Gender and age specific analyses
will be carried out if the sample size allows for meaning-
ful analyses. In general, women, children and elderly
have a higher health care utilisation than other groups,
and therefore have a higher a priori risk of having anti-
biotics prescribed. Consequently, they may show higher
rates of resistance and/or other resistance patterns. The
frequency of prescribed antibiotics will be expressed as
a rate per 1000 listed patients. The distribution of the
different types of antibiotics will be calculated as pro-
portions of all antibiotics prescribed (the ‘market share’).
To test our hypothesis and analyse the congruency of
the resistance and prescription data we will calculate the
odds of receiving an effective antibiotic on a national
level. This ‘effectiveness rate’ will be calculated per
country by multiplying the “market share” in prescrip-
tions of a specific antibiotic with the established antibio-
tic resistance rate of the bacterium (e.g. if 50% of the
prescribed antibiotics is penicillin and 20% of all bac-
teria is resistant to penicillin, penicillin’s effectiveness
rate is 50% × (100%-20%) = 40%). The effectiveness rate
will be calculated per country for each combination of
antibiotic and bacterium. The sum of the effectiveness
rates is an indicator for the appropriateness of prescrib-
ing antibiotics in each country.
Since we use hierarchical data we will use a multilevel
design to assess this appropriateness. Data are analysed
with STATA and MLwiN for multilevel modelling.
Potentially confounders will be included in the model to
adjust for these variables.
Discussion
Strengths and limitations
This study will provide data from nine European coun-
tries on community based resistance patterns and anti-
biotic prescription patterns in primary care, thus
assessing the appropriateness of prescribing antibiotics.
Our integrated data set with a range in prescription and
resistance patterns is powerful and fills the gap in
knowledge concerning community resistance patterns.
We will not only provide information on resistance pat-
terns, but also relate them to prescription behaviour and
treatment guidelines. To improve the quality of pre-
scribing it is important to monitor antimicrobial resis-
tance and usage data on a national level and benchmark
these by comparisons with other countries [34].
Our first intent was to measure resistance in a ran-
dom sample of the general population. Due to practical
reasons this proved not to be feasible. The opportunistic
sampling method that was chosen instead is potentially
prone to selection bias. With our stratification methods
we will be able to reduce this bias and be able to con-
duct analyses concerning several age groups. In the UK,
we are using a different design, where patients swab
themselves. This may lead to a specific selection of
patients. However, since we also measure background
variables we are able to compare the participants’ char-
acteristics with those in other countries. Also, since we
only measure at one point in time we cannot indicate a
causal relationship between prescription behaviour and
resistance patterns. However, our study will produce
valuable data on a public health level.
Implications
Our consistent design throughout Europe provides an
important insight into the appropriateness of prescribing
antibiotics. With our results, we will be able to make
evidence-based recommendations for antibiotic treat-
ment guidelines. Clinicians and policy makers can both
profit from this knowledge. By improving antibiotic use
and decreasing resistance at local levels, we can move
towards controlling the resistance problem in Europe. It
would be valuable to continue monitoring resistance
patterns in the community in the future.
Additional material
Additional file 1: Laboratory Protocol. Laboratory Protocol for isolating
S. aureus and S. pneumonia.
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